Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Axsome Therapeutics to similar businesses based on the strength of its risk, institutional ownership, profitability, dividends, earnings, analyst recommendations and valuation.
Analyst Ratings
This is a summary of current ratings and recommmendations for Axsome Therapeutics and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Axsome Therapeutics | 1 | 2 | 17 | 1 | 2.86 |
| Axsome Therapeutics Competitors | 7806 | 13897 | 25803 | 1039 | 2.41 |
Axsome Therapeutics currently has a consensus price target of $267.58, suggesting a potential upside of 89.81%. As a group, “Pharmaceuticals” companies have a potential upside of 24.95%. Given Axsome Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than its peers.
Profitability
This table compares Axsome Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Axsome Therapeutics | -18.18% | -198.73% | -22.03% |
| Axsome Therapeutics Competitors | -2,380.61% | -219.90% | -15.56% |
Valuation and Earnings
This table compares Axsome Therapeutics and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Axsome Therapeutics | $638.50 million | -$183.17 million | -46.07 |
| Axsome Therapeutics Competitors | $3.53 billion | $3.17 billion | 552.64 |
Axsome Therapeutics’ peers have higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Volatility & Risk
Axsome Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Axsome Therapeutics’ peers have a beta of -3.79, indicating that their average stock price is 479% less volatile than the S&P 500.
Summary
Axsome Therapeutics beats its peers on 9 of the 12 factors compared.
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}